This content is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Read more.
Marsden360
Marsden360
Who is eligible for the Marsden360 test?
Transcript
We can use this test for patients who present who look to have
advanced cancer, such as, for example, lung, pancreatic and bile duct
cancer, to get a much faster diagnosis by taking a blood test rather
than putting them through the standard biopsy programme which
takes much longer to get a diagnosis. And this often allows us to get
patients onto treatment within five days of presentation, which is
fantastic for patients.
There are also patients, for example, with metastatic breast cancer, who may, for example, be progressing on endocrine treatment and would potentially be eligible for drugs such as elacestrant if we can find ESR1 mutations on ctDNA. So that's another really big group of patients.
And then there are patients who present with more advanced cancer where you may be wanting to look for other molecular markers where it's more difficult to biopsy their disease, where you want to be able to take a sample of their blood and look for those molecular markers to see which drugs they might be most suitable for.
And then the final group of patients are patients who present with carcinoma of unknown primary or CUP, where they have metastatic disease and you're trying to figure out where the primary may be.
By doing molecular profiling on ctDNA, we can look at the particular genes that are mutated for that patient and give you a much more likely tissue of origin which narrows down the number of additional tests that patients have to have to try and pinpoint where the primary is. And also allows us to look for a molecularly matched treatment because we know that patients who have a molecularly matched treatment with CUP have much longer survival and much better outcomes.
There are also patients, for example, with metastatic breast cancer, who may, for example, be progressing on endocrine treatment and would potentially be eligible for drugs such as elacestrant if we can find ESR1 mutations on ctDNA. So that's another really big group of patients.
And then there are patients who present with more advanced cancer where you may be wanting to look for other molecular markers where it's more difficult to biopsy their disease, where you want to be able to take a sample of their blood and look for those molecular markers to see which drugs they might be most suitable for.
And then the final group of patients are patients who present with carcinoma of unknown primary or CUP, where they have metastatic disease and you're trying to figure out where the primary may be.
By doing molecular profiling on ctDNA, we can look at the particular genes that are mutated for that patient and give you a much more likely tissue of origin which narrows down the number of additional tests that patients have to have to try and pinpoint where the primary is. And also allows us to look for a molecularly matched treatment because we know that patients who have a molecularly matched treatment with CUP have much longer survival and much better outcomes.